Conference Programme

Thursday 23rd May 2019
6.00pm-8.00pm Ice Breaker Reception-Thistle Trafalgar Square, Whitcombe Street, WC2H 7HG

Friday 24th May 2019

Day One
9.00-9.30 Registration
9.30-9.35 Harry Cotterell – Welcome
9.35-9.40 Professor Angus Dalgleish – Introduction

Session One: Car-T cells immunotherapy, from T cells to ultimate adoptive immunotherapy

9.40-10.10 Carl June – CAR T cells Now and Then – SITC Sponsored

10.10-10.35 Robert Hawkins – TIL – the gateway to adoptive cell therapy for solid tumours

10.35-11.00 John Maher – T4 CAR T-cell immunotherapy of refractory head and neck cancer

11.00-11.25 TEA

11.25-11.50 Adrian Hayday – A natural system for discriminating normality from malignancy

11.50-12.00 Alexei KirkinProffered Paper -Adoptive immunotherapy of cancer: priming through DNA demethylated T helper cells

12.00-12.10 Lucine Marotte – Proffered Paper – Inactivation of PDCD1 gene in melanoma-specific CD8+ T lymphocytes

12.10- 12.20 Gaia Zuccolotto – Proffered Paper – Anti-hPSMA CAR engineered NK-92 cells: An Off-The-Shelf cellular therapeutic for targeted elimination of prostate cancer cells

12.20-12.30 Poster Discussion time

12.30-1.20pm Lunch & poster viewing

Session Two: How to enhance check point inhibitor activity

1.20-1.50 Samra Turajlic – The neoantigen landscape in cancer and response to immunotherapy

1.50-2.20 Raj Chopra – Small molecule modulators of antigen presentation

2.20-2.40 Richard Vile – Proffered Paper – APOBEC3B-mediated Mutation Induces Heteroclitic Neoepitopes for Cancer Immunotherapy

2.40-3.10 Samir Khleif – Reversing check point inhibition resistance

3.10-3.30 Rachael Zemek – Sensitisation of the tumour microenvironment to immune checkpoint blockade

3.30-4.00 TEA

4.00-4.20 Viktor Umansky – Targeting myeloid-derived suppressor cells in melanoma by low-dose chemotherapy

4.20-4.40 Sarah HowlettProffered Paper – Negative impact of antibiotic administration prior to commencement of immunotherapy across multiple tumour sites

4.40- 5.00 Natasha Brockwell – Impact of tumor inherent interferons on immune reactivity and personalized therapy in triple negative breast cancer

5.00-5.30 Professor Angus Dalgleish – Presentation of current data on reversing check point resistance followed by panel discussions

5.30-6.30 Networking Reception and Poster Viewing at the Royal Society

Saturday 25th May 2019

Day Two
Session Three: The role of Cannabinoids such as CBD, CBG etc in the enhancement of anticancer activity

9.00-9.15  Pan Pantziarka – Repurposed Drugs and Onco-Immunology

9.15-9.40  Marco Falasca – Use of Cannabinoids to enhance response to chemotherapy

9.40-10.00 Nadine Hall – Investigating the role of Cannabinoids in Cancer

10.00-10.30 Roger Pertwee  -Novel potential therapeutic uses of certain plant and synthetic cannabinoids revealed by their pharmacological properties

10.30-10.40 Julian Kenyon  – Proffered Paper  –  Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

10.40-11.00 TEA

11.00-11.25 Angus Dalgleish – Presentation of current data on cannabinoids in cancer followed by panel discussions

Session Four: Vaccines and other Immunotherapies

11.25-11.40 Heinrich Roder – Immune phenotyping from measurements of the circulating proteome

11.40- 12.00 Bastian Schilling – Neoantigens and cryptic peptides: novel concepts for immunotherapy of malignant melanoma

12.00-12.20 Vincenzo Bronte – Modulation of apoptosis and transcriptional activity in tumor-educated, immunosuppressive monocytes

12.20-12.35 Katherine Cook – Stress induced post translational modifications to self peptides are effective targets for cancer vaccines

12.35-1.30 Lunch and poster viewing

1.30-2.00 Michael Shurin – New therapeutic targets: Tumor innervation

2.00-2.30 Bernard Fox  -Cancer Immunotherapy in Evolution: Vaccination, Co-stimulation and Checkpoint Blockade – SITC Sponsored

2.30-2.45 Robin WeissProffered Paper – Can we learn lessons about immune control from transmissible tumours?

2.45-3.15 Paul Sondel – Activation of innate and adaptive immunity to induce an in situ vaccine

3.15-3.35 TEA

3.35-3.50 Simon Wain- HobsonProffered Paper – HLA-G as a powerful immune checkpoint and tumor specific antigen for cancer immunotherapy

3.50-4.35 Irving WeissmanHolbrook Kohrt Memorial Lecture – Normal and Neoplastic Stem Cells

4.35-4.40 Poster Prize Presentation

4.40-5.30 Angus Dalgleish – Collaboration session

7.00pm -10.00  Speakers’ Dinner, Royal Automobile Club (RAC).  Invitation only.